The New Year is off to a swift start here at Novella Clinical following an eventful 2016. Last month was especially exciting as we welcomed a new division through the acquisition of the Phase II-IV Clinical Trials Division (CTD) of TKL Research. TKL’s CTD is now the dermatology division of Novella Clinical and, with the transaction, we gained new colleagues and customers for 2017.
The addition of a dedicated dermatology division helps address the continued industry need for therapeutic and delivery specialization. Importantly, the outsourcing market for dermatology clinical trials is increasing and we are now well positioned to better serve our customers.
Further, the dermatology division complements Novella’s existing capabilities as a collection of specialty CRO solutions and expands our therapeutic expertise. The Novella Clinical brand encapsulates the specialized oncology and medical device/diagnostic services we offer to customers; I’m proud to say that specialization now includes dermatology. This is an exciting time at Novella and I look forward to continuing to deliver strong customer service and therapeutic excellence for our customers in 2017.
Learn more at www.novellaclinical.com/dermatology.